On 22 July China's Keyi Pharmaceutical granted US-based Erigen LLC exclusive global rights (excluding Greater China, India, Turkey and Russia) to its BCMA/CD19 dual-target CAR-T therapy KQ-2003. The agreement includes USD 15 million in near-term milestones and up to USD 1.32 billion in development/regulatory payments plus USD 800 million in sales royalties. KQ-2003, the world’s third most advanced BCMA/CD19 CAR-T candidate, features parallel architecture design to enhance persistence and reduce relapse risks.

Keyi retains Greater China rights for KQ-2003 and potential off-the-shelf CAR-T derivatives. The deal follows AstraZeneca's acquisition of Gracell Biotechnology, another leader in dual-target CAR-T development. KQ-2003's signal domain optimisations aim to address durability challenges in haematological malignancies.

According to PharmCube's NextBiopharm® database, there are 33 companies actively developing BCMA/CD19 CAR-T therapy projects globally, some of which are listed below. Click here to request a free trial for NextBiopharm®.